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Abstract 
Opportunistic oral infections caused by Candida albicans, have become a frequent problem in 
immunocompromised patients. Management of such infections is limited, due to the low number of 
antifungal drugs available, their relatively high toxicity and the emergence of antifungal resistance. 
Given these issues, our investigations have focused on novel derivatives of the antifungal antibiotic 
Nystatin A1, generated by modifications at the amino group of this molecule. The aims of this study 
were to evaluate the antifungal effectiveness and host cell toxicity of these new compounds using an in 
vitro model of oral candidosis based on a reconstituted human oral epithelium (RHOE). Initial studies 
employing broth microdilution, revealed that against planktonic C. albicans, Nystatin A1 had lower 
minimal inhibitory concentration (MIC); however, Nystatin A1 was also markedly more toxic against 
human keratinocyte cells (HaCaT), compared with novel derivatives. Interestingly, using live/dead 
staining to assess C. albicans and tissue cell viability after RHOE infection, Nystatin A1 derivatives 
were more active against Candida with lower toxicity to epithelial cells than the parent drug. Lactate 
dehydrogenase activity released by the RHOE also indicated a four-fold reduction in tissue damage 
when certain Nystatin derivatives were used, compared with Nystatin A1. Furthermore, compared with 
Nystatin A1, colonization of the oral epithelium by C. albicans was notably reduced by the new polyenes. 
In the absence of antifungal agents, confocal laser scanning microscopy showed that C. albicans 
extensively invaded the RHOE. However, the presence of the novel derivatives greatly reduced or totally 
prevented this fungal invasion.  
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Introduction 
During recent decades, the number of people with immune system disorders has increased markedly. 
Such individuals include those who are diabetic, patients with haematological malignancies such as 
acute leukaemia, cancer patients who are exposed to high doses of chemotherapy or radiation therapy, 
transplantation surgery patients and HIV-positive persons [1]. According to World Health Organization 
reports, the number of HIV infected humans in 2008 reached 33.4 million [2]. In the same year, the 
number of cancer cases amounted to 20 million [3], whilst, latest data show that 347 million people 
suffer from diabetes mellitus [4]. Associated with the chronic problems of these immunocompromised 
individuals, are the added complications of opportunistic infections, of which oral candidosis (OC) is 
extremely prevalent [5-7].  
 In addition to the above, there are other debilitating factors that enhance the risk of Candida infection. 
For example, an increased prevalence of oral candidosis is evident amongst elderly individuals, pregnant 
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women and newborn babies, as well as in people with some form of nutritional deficit, such as iron or 
vitamin B12 deficiency [8, 9]. Moreover, Candida overgrowth is often promoted by excessive use of 
medications, especially broad-spectrum antibiotics, which disturb the natural community of the bacterial 
microflora, and corticosteroids, which can suppress nonspecific inflammatory responses. Apart from 
systemic risks, local predisposing factors include an insufficient degree or absence of oral hygiene, 
tobacco smoking, wearing of dental prostheses, a diet rich in carbohydrates and hyposalivation [8, 9]. 
 The principal causative agent of oral candidosis is Candida albicans. This polymorphic fungus 
frequently colonises the oral cavity and digestive tract surfaces of humans as a harmless commensal. 
However, as mentioned above, when individuals become debilitated C. albicans overgrowth can arise, 
resulting in infection [10, 11].  
 Clinically, in its primary form, oral candidosis presents on the mucosa of the pharynx and 
oesophagus.  
Meanwhile, secondary lesions can lead to symptoms of systemic or disseminated mycoses. Primary oral 
candidosis can be widespread and is divided into three clinically distinct types. Pseudomembranous and 
erythematous candidosis manifest as either acute or chronic variants, whilst hyperplastic infection 
develops only as a chronic condition. Each type of infection has a different clinical presentation, occurs 
in specific groups of patients and often requires different approaches of treatment [12, 13].  
 Currently, two main classes of antifungal drugs are used in the management of oral candidosis, 
namely, azole and polyene agents [12-14]. Their antifungal action results from the presence of 
ergosterol, as an essential component of the fungal cell membrane. Azole compounds inhibit the fungal 
cytochrome P450 (CYP) dependent enzyme, lanosterol 14 α-demethylase, which participates in the 
ergosterol biosynthesis pathway. As a result, ergosterol depletion and accumulation of improper sterols 
disturb the correct structure and functioning of the cell membrane and finally inhibit fungal cell growth 
[13-15]. 
The majority of azole antifungals, of which fluconazole is the main representative, exhibit a high 
bioavailability after oral administration. However, through inhibition of the human cytochrome P450 
(CYP) enzyme system, azoles can also initiate undesirable drug-drug interactions. These interactions 
may reduce drug absorption or increase the risk of adverse effects, which are especially dangerous in 
patients receiving immunosuppressive or cardiovascular therapy [15]. Similarly problematic, is the 
emergence of Candida resistance to azoles, mainly arising due to point mutations in the azole-binding 
site of α-demethylase and/or by overproduction of multi-drug efflux pumps that are able to actively 
expel the drug from the fungal cell [16].  
In contrast to azole compounds, polyene antibiotics bind to ergosterol directly and form 
transmembrane channels. These membrane channels significantly increase membrane permeability and 
cause leakage of cellular contents. Fungicidal action and low incidence of fungal resistance are the most 
advantageous features of polyenes. However, despite greater affinity to the fungal sterol, ergosterol, 
there is a tendency for polyenes to also interact with the human membrane component, cholesterol, and 
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this can lead to numerous side effects [17]. Moreover, low absorption through the gastrointestinal tract 
creates many difficulties in drug administration and restricts the use of polyenes in oral candidosis to 
topical applications [12, 17].  
 Without doubt, current antifungal chemotherapy has a number of key limitations, and the lack of 
highly effective and selective antifungal drugs to adequately treat the conditions often results in 
recurrence of Candida infections [18]. Consequently, there is an urgent need for the development of 
novel and advanced antifungal agents that overcome the problems of those currently available. One 
proposed strategy is rational chemical modification, designed to improve existing properties of native 
drugs [19-21].  
 Prior to the present study, efforts had been made to modify the structure of the polyene antibiotic, 
Nystatin A1 (Fig. 1) to reduce toxicity and increase water solubility. Previous reports have shown that 
an amino group of the polyene molecule plays an essential role in membrane interactions, whilst the 
presence of additional polar functional groups may improve solubility in water [19, 21, 22]. Therefore, 
novel N-substituted derivatives of Nystatin A1 have been recently synthesized as potential antifungal 
agents [23].  
The aims of our investigations were to assess the effectiveness and toxicity of these novel Nystatin 
A1 derivatives using an in vitro model of oral candidosis. Antifungal activity against C. albicans and 
cytotoxic effects on a human keratinocyte cell line were initially examined. Subsequently, Candida 
infection of a reconstituted human oral epithelium (RHOE) was successfully developed, and the extent 
of epithelial cell damage/viability was measured using lactate dehydrogenase activity and live/dead 
staining. The degree of tissue colonization and profile of tissue invasion by C. albicans was analysed 
using immunofluorescence labeling and confocal laser scanning microscopy (CLSM). Candida viability 
was also determined by live/dead staining and CLSM imaging. The effect on these measured parameters, 
was determined post treatment with different Nystatin A1 derivatives and based on these experiments, 
identification of novel Nystatin A1 derivative(s) with appropriate function and reduced toxicity were 
made. 
 
Materials and Methods 
 
Candida albicans and reconstituted human oral epithelium 
All experiments were performed using the reference strain of C. albicans ATCC 10231. Initial cytotoxic 
effects of antifungal drugs were tested using a human keratinocyte cell line (HaCaT) from the collection 
of the School of Dentistry, Cardiff University (UK). A commercially available reconstituted human oral 
epithelium (RHOE, SkinEthic Laboratories; Nice, France) that had previously been established as an in 
vitro tissue model of oral candidosis [24, 25] was utilised in these infection studies.  
Antifungal compounds 
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Nystatin A1 (Nys) was obtained from Sigma Aldrich (Poole, UK) and the novel Nystatin A1 derivatives 
were designed and synthesised at BLIRT S.A. Company, Gdansk (Poland) [23] and the Department of 
Organic Chemistry and Department of Pharmaceutical Technology & Biochemistry at GUT (Poland). 
All derivatives were divided into classes depending on the functional group attached to the nitrogen 
atom in the native macrolide structure and selected representatives (Nys1, Nys2, Nys4, Nys5, Nys6, 
Nys7, Nys8) were the focus of these studies. These derivatives form water-soluble salts. N-fructosyl 
Nystatin A1 (Nys3) [26] was used as a reference derivative of Nystatin A1. Stock solutions of Nystatin 
A1 and its derivatives were prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich, Poole, UK). As the 
native Nystatin A1 is water-insoluble and requires the use of DMSO to make the stock solution, the 
antibiotic derivatives were used not in the form of their water-soluble salts, to ensure the same conditions 
for testing of all compounds.  
Antifungal susceptibility testing  
In vitro antifungal activity of Nystatin A1 and N-substituted derivatives was initially measured based on 
the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI, formerly 
NCCLS), [27] with the exception that a final inoculum density of 1×104 cells ml-1 was used. The 
Minimal Inhibitory Concentration (MIC) was determined for C. albicans using RPMI-1640 medium 
(with L-glutamine and phenol red, without sodium bicarbonate, Sigma-Aldrich, Poole, UK) buffered to 
pH 7.0 with MOPS buffer ([3-(N-morpholino) propanesulfonic acid], Sigma-Aldrich). Appropriate 
solutions of studied compounds previously prepared in DMSO were diluted in the RPMI-1640 medium 
to give final concentration ranges of 0.03125-16 µg ml-1 for Nystatin A1 and 0.250-128 µg ml-1 for the 
new derivatives. The final DMSO concentration in each well was 1% (v/v). Microtitre plates were 
incubated at 30°C and optical absorbance (OD531nm) recorded after 24 h with a plate reader 
(VICTOR3™ Multilabel Counter, Perkin Elmer, Massachusetts, USA). The MIC was defined as the 
lowest compound concentration that provided complete inhibition of visible growth. A half maximal 
inhibitory concentrations (IC50-C) were also estimated by preparing graphs from measured optical 
density (OD531nm) values as a function of drug concentration and fitting these data to the sigmoidal 
dose-response equations using Origin Pro 8.1 software (OriginLab Corporation, Northampton, USA). 
Susceptibility tests were repeated on three separate occasions. 
Cytotoxicity studies of antifungal compounds 
The in vitro cytotoxic effects of Nystatin A1 and the novel derivatives on human cells was undertaken 
using a keratinocyte cell line (HaCaT) in DMEM medium containing high glucose concentration and L-
glutamine (Lonza Group Ltd., Basel, Switzerland) supplemented with 10% Fetal Bovine Serum (FBS) 
and penicillin/streptomycin (100 U ml-1 and 100 µg ml-1, respectively, Lonza Group Ltd.). After washing 
twice with phosphate-buffered saline (PBS, pH=7.0), HaCaT cells were harvested using trypsin-EDTA 
solution (Lonza Group Ltd.) and the number of cells enumerated with a haemocytometer before 
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adjustment to a density of 2×106 cells ml-1 in DMEM medium. Serial doubling dilutions of the 
keratinocyte cell suspension was performed in a 96-well tissue culture plate (Sarstedt, Nümbrecht, 
Germany) which also included a growth control commencing at 1×105 cells ml-1.  
For drug testing, 100 µl of 2×104 cells per well were seeded in each well with the same volume of 
appropriately diluted compound in culture medium. The antifungal concentration range was 12.5-300 
µg ml-1 and the final DMSO concentration in all microtitre wells was 1% (v/v). Keratinocytes were 
incubated for 3 days at 37°C in a humidified atmosphere containing 5% CO2. After incubation, cell 
viability was determined using the Cell Counting Kit-8 (Sigma-Aldrich). This colorimetric assay was 
based on the reduction of water-soluble tetrazolium salt to a coloured product – formazan by active 
dehydrogenases of viable cells. The amount of water-soluble formazan dye was therefore directly 
proportional to the number of living cells. After 3 days, 100 µl of the removed culture medium was 
replaced by 100 µl of 10-fold diluted CCK-8 reagent. Incubation was continued for another 4 h and the 
absorbance was then measured at 450nm in a plate reader (FLUOstar Omega; BMG LABTECH GmbH, 
Ortenberg, Germany). Cell viability was evaluated by plotting optical density values (OD450) as a 
function of drug concentration and the IC50-H (half maximal inhibitory concentration) value calculated 
by fitting the results to the sigmoidal dose-response equations in the Origin Pro 8.1 software. For each 
compound, the experiments were performed in triplicate. 
In vitro tissue model of oral candidosis treated with antifungals 
To further examine antifungal effectiveness of the compounds, an in vitro tissue model of oral candidosis 
was utilised. For this purpose, a reconstituted human oral epithelium (RHOE) and C. albicans were 
used. Before each experiment, C. albicans was cultured on Sabouraud Dextrose Agar (Oxoid Ltd., 
Hampshire, UK) for 48 h at 30°C and a portion of colony growth then re-suspended and incubated in 
Yeast Nitrogen Base medium (0.67% YNB without amino acids; BD Diagnostics, Cowley, UK) 
supplemented with 0.5% glucose (Merck, Darmstadt, Germany) for 12 h with gentle agitation at 37°C. 
Cells were then harvested by centrifugation, washed three times with sterile phosphate-buffered saline 
(PBS, pH=7.0) before resuspension in fresh PBS.  
To establish the in vitro tissue infection, Candida yeast were enumerated in an Improved Neubauer 
haemocytometer and adjusted to a final concentration of 2×106 cells ml-1 in Maintenance Medium 
(SkinEthic Laboratories, Nice, France), used for RHOE cultivation. Finally, RHOE tissue inserts (0.5 
cm2, age day 5) were transferred to a sterile 24-well tissue culture plate (Sarstedt, Nümbrecht, Germany) 
and inoculated with 1 ml of standardized yeast suspension (2×106 cells ml-1). A control of non-infected 
tissue with 1 ml of medium devoid of Candida was also prepared. All tissues were incubated for 6 h at 
37°C in a humidified atmosphere with 5% CO2. Supernatants were then removed, and 1 ml of the 
antifungal compound solutions in Maintenance Medium added to the tissue surfaces. Experiments were 
performed at a total drug concentration of 150 µg ml-1 in 1% (v/v) DMSO. Maximal fungal infection 
controls were obtained by incubation of RHOE tissue with Maintenance medium incorporating 1% (v/v) 
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DMSO. Similarly, non-infected tissue controls, utilised replacement of supernatant with fresh medium 
containing 1% DMSO. After overnight incubation, supernatant was collected for lactate dehydrogenase 
measurement and the tissues were rinsed with phosphate-buffered saline. All inserts were divided in 
half, with one portion used for live/dead staining and the other portion prepared for CLSM. All 
experiments were performed on five separate occasions. 
Live/dead assay of infected tissues 
Determination of C. albicans viability after antifungal treatment was based on the use of live/dead 
staining. Portions of fresh (i.e. not fixed) RHOE tissues post-infection, were placed on to microscope 
slides and 100 µl of a fluorescent dye mixture (25 µM Syto9 and 15 µM propidium iodide, Molecular 
Probes-Invitrogen, Paisley, UK) directly added. The green fluorescing nucleic acid dye, Syto9, was used 
to stain both live and dead cells, whilst the red fluorescing dye, propidium iodide, was used to stain only 
dead cells. Samples were incubated for 30 min at 37°C in the dark, transferred to clean slides and overlaid 
with Vectashield Mounting Medium (H-1000, Vector Laboratories, Inc., Burlingame, CA) for 
prevention of dye photo bleaching. Stained tissues were observed by CLSM using a Leica TCS SP2 
AOBS spectral confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany). Tissue halves 
were scanned through a 15-µm depth with a ×40 objective lens at a Z-step of approximately 0.5 µm. To 
eliminate spectral bleed-through between fluorescent probes, sections were scanned using appropriate 
settings for sequential fluorescence recordings of Syto9 (ex/em max: 480/500nm) and propidium iodide 
(ex/em max: 490/635nm). Images were presented as maximum intensity type reconstructions and were 
used for fluorescent areas enumerations. The experiments were performed in triplicate. 
Live/dead cell determination 
The effect of the tested compounds on both Candida albicans and RHOE cell viability was determined 
from confocal microscopy images. Total area of green and red fluorescence in relation to each image 
area was calculated using an image analysis program– ImageJ 1.46r (Wayne Rasband, National Institute 
of Health, USA). Firstly, the image was divided into green and red channels and the function of threshold 
intensity was utilised. Subsequently, the green and red area measurements for both cell types (Candida 
and epithelial cells) were made with the use of the ‘Analyze Particles’ ImageJ tool. All calculations were 
made for three separate images. For easier comparison of all data, green and red fluorescent areas for 
each type of cell in a single image were summed, assumed as a total and the percentage of live and dead 
cells computed separately for C. albicans and epithelial cells. Results were presented as a mean of three 
independent images. 
Tissue sections preparation for CLSM 
Tissue colonisation and invasion by C. albicans in the presence and absence of antifungal agents was 
determined by CLSM after immunofluorescent labeling of tissue sections. For section preparation, 
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infected tissues were fixed in formalin for 24 h at 4°C and embedded in paraffin wax. Tissues sections 
(20 µm) were generated and placed on Histobond + coated microscope slides (Raymond A Lamb, East 
Sussex, UK). Sections were then de-waxed, re-hydrated and heated twice for 5 min at 95°C in 10 mM 
citrate buffer (pH=6.0) to break formalin cross-links and expose target antigens. After cooling, sections 
were washed in water (×3 for 2 min) and potential non-specific binding sites blocked with normal goat 
serum (Sigma-Aldrich) at a 1:20 dilution for 30 min at room temperature. Subsequently, sections were 
incubated overnight at 4°C with a mouse monoclonal IgG pan-cytokeratin primary antibody at 2 µg ml-
1 (Santa Cruz Biotechnology, Inc., Dallas, USA). Tissue sections were then washed in phosphate 
buffered saline (PBS; ×2 for 5 min) and labeled with Alexa Fluor 488 goat anti-mouse IgG secondary 
antibody (5 µg ml-1; Molecular Probes-Invitrogen, Paisley, UK) for 35 min at room temperature. After 
washing, samples were treated with 25 µg ml-1 Concanavalin A lectin conjugated with Alexa Fluor 594 
(Molecular Probes-Invitrogen) for 20 min and then stained with Hoechst 33258 dye (2 µg ml-1; Sigma-
Aldrich) for another 30 min at room temperature. All antibodies and dye solutions were made up in PBS 
containing 0.1% Tween 20 (Sigma-Aldrich).  
Stained sections were washed, mounted with Vectashield Mounting Medium (H-1000, Vector 
Laboratories) and analyzed by CLSM using a Leica TCS SP2 AOBS spectral confocal microscope 
(Leica Microsystems GmbH). Sections were scanned sequentially through their depth using appropriate 
scan settings for sequential fluorescence recording of Alexa 488 (ex/em max: 495/519nm), Alexa 594 
(ex/em max: 590/617nm) and Hoechst 33258 (ex/em max: 352/461nm) as described previously. Images 
were presented as maximum intensity reconstructions. Candida albicans were represented by red Alexa 
594 fluorescence, keratinocytes by green Alexa 488 fluorescence and cell nuclei by blue Hoechst 33258 
fluorescence. The experiments were performed in five replicates.  
For precise determination of the effect of tested compounds on the epithelial colonisation by Candida 
strain, the thickness of fungal layers on RHOE sections were measured using CLSM images . 
Calculations were made with the ImageJ 1.46r program by dividing the area surface by the width of the 
Candida layer. Results were presented diagrammatically as a mean of three separate images. 
Measurement of lactate dehydrogenase activity 
The extracellular activity of lactate dehydrogenase (LDH) released from epithelial cells was monitored 
as an indicator of tissue cell damage. Enzyme activity was measured from collected culture medium 
after infection of RHOE tissues with C. albicans ATCC 10231 and treatment with antifungal drugs 
dissolved in DMSO, or RHOE in the presence of solvent alone. To investigate the effect of compounds 
on epithelial cells in the absence of Candida, controls of uninfected tissues as well as those incubated 
with 1% (v/v) DMSO or with just 150 µg ml-1 of antifungals were also tested. For determination of LDH 
activity, a CytoTox–ONE Homogeneous Integrity Assay kit (Promega, Madison, USA) was used. The 
method was based on the formation of a fluorescent product as a result of the coenzyme NADH 
diminishing during the LDH catalyzed reaction. The intensity of fluorescence was analyzed with a plate 
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reader (FLUOstar Optima, BMG LABTECH GmbH, Ortenberg, Germany) at appropriate excitation 
544nm and emission 590nm wavelengths, and was proportional to the number of damaged cells. The LDH 
activity of culture medium alone was subtracted from LDH activity of tissue samples and results 
expressed as a cytotoxicity percentage relative to the maximum enzyme release (LDH activity from 
Candida infected, untreated controls). The experiments were performed in five replicates for infected 
tissues and in duplicate for uninfected ones.  
Statistical analysis 
Statistical analysis of data was performed using Origin Pro 8.1 software (OriginLab Corporation, 
Northampton, USA). The results of fluorescent area calculations, LDH release measurements as well as 
Candida biofilm thickness and HaCaT cells viability for Nystatin A1 and the novel derivatives were 
compared using a one-way analysis of variance (ANOVA) by applying a Tukey multiple comparisons 
test. Statistically significant differences were set at P < 0.05. 
Results 
In vitro antifungal and cytotoxic effect of Nystatin A1 and novel derivatives 
The in vitro antifungal activity of tested compounds was measured according to the CLSI protocol. The 
effect of N-substituted derivatives and native Nystatin A1 was determined against C. albicans ATCC 
10231 and defined by the MIC providing complete inhibition of fungal growth. A half maximal 
inhibitory concentration (IC50-C, where the latter C defines Candida) was also calculated.  
Our studies showed that all examined derivatives were active against Candida; however, they exhibited 
somewhat higher MIC values compared with the native drug (Table 1).  
Amongst the tested derivatives, good antifungal activity with MIC ranging of 2 µg ml-1 was 
demonstrated by Nys5 with MICs of 4 µg ml-1 evident with Nys1, Nys2, Nys7 and Nys8. The similar 
antifungal effect of these derivatives on C. albicans seemed to be independent of the functional group 
present. According to IC50-C calculations, Nys5 was selected (1.19 µg ml-1) as the most potent 
antifungal Nystatin A1 derivative. It was also interesting, that some derivatives, namely Nys1 and Nys7, 
although they represented different types of modifications, were characterised by identical antifungal 
action, as they both had the same MIC and IC50-C (2.81 µg ml-1) values.  
To determine cytotoxic effects of Nystatin A1 and its derivatives, we used a keratinocyte cell line 
(HaCaT) because these cells are the major types within a multilayered human epithelium in vivo. The 
data were presented in the form of IC50 values (IC50-H, where H represents HaCaT) obtained from 
graphs of cell viability as a function of a drug concentration. The substitution of the amino group in the 
Nystatin A1 molecule was beneficial and resulted in a reduced toxicity of new polyene compounds 
(Table 2). We found that semisynthetic derivatives had no significant effect on the vitality of human 
keratinocytes up to the concentration of 300 µg ml-1, since it was impossible to calculate the 
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concentration, which inhibits the growth of HaCaT cells at 50%. In contrast, the native Nystatin A1 
displayed high cytotoxicity to keratinocytes with the IC50-H value at the level of 50.82 µg ml-1.  
 For further investigations of novel Nystatin A1 derivatives, we selected Nys5, due to it having the 
lowest IC50 value found in the antifungal activity determination and two other derivatives: Nys1 and 
Nys7, as representatives of different structural groups.  
Viability of Candida albicans and epithelial cells in the model of fungal infection 
To examine whether novel derivatives had the ability to kill C. albicans during in vitro RHOE infection 
and to assess the influence of these agents on epithelial cells viability, an in vitro infection model was 
utilised. For this purpose, we firstly incubated human oral epithelium with C. albicans ATCC 10231 for 
6 h and then exposed infected tissues to antifungal compounds at the concentration of 150 µg ml-1 for 
another 16 h. Following this process, tissues were stained using a live/dead assay and visualized by 
confocal scanning laser microscopy (Fig. 2). 
 All infected tissues (Fig. 2B-F) were colonised by C. albicans. To compare CLSM images, the 
relative percentage of green and red fluorescent areas were calculated and the overall ratio of live and 
dead cells determined. The red fluorescent nuclear dye, propidium iodide does not enter into living cells 
and was therefore used to detect only dead cells. In contrast, Syto9, a green fluorescent nucleic acid dye, 
stained both live and dead cells.  
Compared with the control treated with only 1% (v/v) DMSO, where 99% of Candida cells were green 
(Fig. 2B), both the natural Nystatin A1 and selected derivatives, namely Nys1, Nys5 and Nys7 resulted 
in red fluorescence of C. albicans, typically observed in cell death. The results showed that the new 
Nystatin A1 derivatives were more effective against Candida in the tissue infection compared with the 
native drug alone (P <0.05).  
Based on our calculations (Fig. 3A), the most active compound, Nys7, generated an 88.5% area of 
Candida cells with red fluorescence, whilst treatment with Nystatin A1 resulted in only 35% area of 
dead cells. Incubation with derivative Nys5 resulted in a 77% area of dead Candida compared with 69% 
with Nys1.   
 The viability of tissue keratinocytes was also calculated (Fig. 3B). In the drug-free control (infected 
with C. albicans), we found that 99% of infected epithelial cells exhibited red fluorescence. Treatment 
with native Nystatin A1 resulted in a statistical reduction in epithelial cell death compared with the 
control (P < 0.05), however, high levels of red tissue fluorescence amounting to 78% remained evident. 
Interestingly, treatment using the novel compounds induced significantly lower areas of red (i.e. dead) 
epithelial cells than the parent drug. It was established that both derivatives Nys1 and Nys5 had no 
impact on viability of human keratinocytes in the in vitro model compared with the uninfected tissue 
control (P > 0.05) and almost 90% of these cells remained green (i.e. viable) after treatment. Only Nys7 
demonstrated some toxic effect, since a 48% area of epithelial cells was deemed to be red. 
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 In conclusion, listed Nystatin A1 derivatives caused high levels of Candida cell death and 
demonstrated low toxicity to human oral epithelium.  
Novel antifungal compounds in inhibiting colonisation and invasion of oral epithelium by Candida 
albicans 
Infected tissue treated with antifungals were fixed, sectioned and immunofluorescently labelled to 
analyse the level of tissue colonisation and invasion by Candida. From these studies, the aim was to 
measure changes in the progress of fungal infection and assess whether differences occurred due to the 
presence of new antifungal compounds.  
Our investigations revealed a high ability of C. albicans ATCC 10231 to colonise the surface of the 
human oral epithelium in the drug-free control. There was a high tendency for C. albicans to generate a 
biofilm-like structure, where most of the fungal cells were in the form of hyphae. Moreover, in the 
absence of antifungals, the tissue was completely invaded by the fungal elements, with both hyphae 
(predominantly) and some yeast forms detected even at the base of the epithelium. This resulted in the 
separation of keratinocytes from the membrane insert base and detachment of the epithelium (Fig. 4). 
Compared with uninfected controls, areas of vacuolation in the tissue structure could also be seen as 
further evidence of tissue damage.  
 The action of antifungal compounds significantly inhibited the progress of RHOE infection (Fig. 5). 
After treatment with native Nystatin A1, Candida was still seen to colonise the surface of the epithelium, 
but penetration into the tissue was not observed. The fungal layer was two-fold thinner than in the control 
of solvent alone (1% v/v DMSO; 100.1µm biofilm thickness; Fig. 6), however Candida hyphae were 
still tightly clustered (Fig. 5B).  
Treatment with compound Nys1 did not entirely prevent C. albicans invasion of the RHOE (Table 3), 
although only the upper layers of the epithelium were invaded. Within the tissue, the presence of both 
hyphae and yeast was observed (Fig. 5C). It was also evident that fungal cells were not organised within 
a typical biofilm-like form, as noted with the Nystatin A1 and two other derivatives. In contrast, the 
stratified growth of Candida appeared to be retarded and this resulted in the greatest decrease in the area 
(24.7 µm thick) occupied by the fungal cells on the epithelium surface, when comparing all the tested 
compounds (Fig. 6).  
In the case of the Nys5 derivative treated oral epithelium, the presence of an approximately 35 µm thin 
biofilm formed by Candida cells on the tissue surface was detected. However, the Candida had not 
invaded the oral epithelium, implying a similar effect of this novel Nystatin derivative to the native drug. 
Furthermore, fungal colonisation of the RHOE was less extensive compared with the Nystatin A1 treated 
tissue, where the Candida layer measured 49.4 µm and the structure of the biofilm appeared less densely 
organised (Fig. 5D).  
After treatment with Nys7, the RHOE was covered by thin (31.6 µm) and poorly compacted layer of 
fungal cells, predominantly in hyphal form, similar to that seen in the tissue treated with Nys5. A few 
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Candida were able to invade through the epithelium (Fig. 5E), but this level of invasion was less 
noticeable compared to the tissue treated with Nys1.  
Finally, detachment of the tissue base from keratinocytes layers did not occur under the influence of the 
antifungal agents.  
 Based on these results, Nys5 and Nys7 were deemed the most effective antifungals, due to the fact 
they considerably inhibited the ability of Candida to colonize and invade the oral epithelium. 
Effect of Nystatin A1 derivatives on the release of lactate dehydrogenase from infected tissues 
Activity of LDH released by the RHOE after Candida infection was measured to determine the extent 
of tissue damage induced by Candida in the presence and absence of antifungal compounds (Fig. 7). 
Candida albicans ATCC 10231 induced the maximal level of LDH activity, when the tissue was 
incubated with solvent alone (1% v/v DMSO). Exposure of uninfected tissue to 1% (v/v) DMSO resulted 
in LDH activity below 5%, showing that it was the fungal infection that was responsible for the 
epithelium damage. Nystatin A1 induced release of LDH from Candida infected tissue at the level of 
22%, however this was not statistically different from the enzyme activity level of uninfected and 
Nystatin A1 treated RHOE (20%; P > 0.05).  
Novel Nystatin A1 derivatives reduced LDH activity 4-fold compared with the native compound. In the 
presence of these new polyenes, the extent of LDH activity was comparable to Candida uninfected 
RHOE tissues and no significant (P > 0.05) difference in LDH activity was evident for RHOE treated 
with the different compounds. Although, LDH activity levels for RHOE treated with the Nystatin A1 
derivatives were different from untreated and uninfected tissue control (P < 0.05), they were statistically 
the same as the uninfected tissue treated only with medium at 1% (v/v) DMSO (P > 0.05).   
Discussion 
Since oral candidosis is a commonly encountered opportunistic fungal disease associated with a variety 
of symptoms including inflammation and hypertrophy of the oral mucosa and an enhanced possibility 
of Candida dissemination into the other organs, effective methods to combat oral candidosis are 
required. Amongst the limited armamentarium of drugs for the management of oral fungal infections, 
the polyene antibiotics have historically been the most extensively used, and have significant antifungal 
activity with low incidences of fungal resistance [17]. 
Polyene antifungals are secondary metabolites produced by Streptomyces soil bacteria and consist of a 
macrolactone ring with a range of conjugated double bonds (3 to 8) and several hydroxyl groups. The 
lactone core is connected by a glycoside bond with an amino sugar moiety, namely mycosamine, and 
includes a hemiketal fragment with a carboxylic acid group [28]. The action of polyene compounds is 
related to the formation of ion channels in fungal membranes rich in ergosterol; however interaction, 
albeit to a lesser extent, also occurs in mammalian membranes containing cholesterol. Within this group, 
Nystatin A1 (Fig. 1) is a leading member for the treatment of oral candidosis and for prevention in 
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patients with a high risk of infections recurrence [12, 13, 17]. Unfortunately, due to toxic side effects 
after parenteral use, e.g. sclerosing of veins, chills and fever [29], as well as poor oral distribution 
associated with low water solubility, Nystatin A1 may be only administrated in the form of topical 
preparations. Even then, some formulations like suspensions or rinses have reduced efficiency because 
of saliva dilution and a cleaning action of the oral cavity. Consequently, the effective drug concentration 
and a sufficient duration of contact time with the oral mucosa may not be achieved, leading to a 
therapeutic failure [12].  
 In recent years, considerable effort has been made to circumvent the undesirable features of polyene 
compounds. These studies have involved production of new antibiotic formulations, genetic 
manipulation of biosynthetic products and chemical modification of natural drugs. Two Nystatin A1 
formulations, as liposomal and intralipid, that reduce drug toxicity have subsequently been developed 
[29, 30]. Moreover, clinical trials of liposomal Nystatin A1 have been completed [31], although such 
products are known as very expensive for routine antifungal treatment [32]. Meanwhile, the intralipid 
formulation seems to be a promising, low-cost counterpart, however this remains in the process of 
testing [33, 34].  
Genetic engineering methods are based on manipulation of polyene biosynthetic genes in Streptomyces 
species. During these investigations several new Nystatin-like polyenes have been discovered, with a 
few of them characterised with better solubility in water and lower toxicity [35], e.g. Nystatin A1 
heptaene S44HP, described by Bruheim et al. [36]. Nevertheless, biosynthetic and genetic engineering 
techniques tend to be time-consuming and in many cases, result in limited yields of fermentation 
products [37]. Chemical modification of antibiotic structure appears to be amongst the quickest and 
most cost effective means to design new improved polyene antifungals. Therefore, a number of polyenes 
derivatives have been synthesised and some of them have preferable selective toxicity parameters [38-
40]. However, previous efforts have largely focused on Amphotericin B, a polyene predominantly used 
in the treatment of systemic mycoses [41].  
 Based on the above information, our research has focused on Nystatin A1, noting that relatively little 
had been undertaken on to chemically improve this polyene antibiotic. As a result, we present novel 
Nystatin A1 derivatives, modified at the amino group, as low toxic and efficient antifungal compounds 
for use in combating oral Candida infection. In this present study, we have used these agents, for the 
first time, to treat in vitro Candida infections of RHOE. Due to the similarity of this tissue model to in 
vivo conditions, it offers a potential alternative to animal research models [25, 42] in assessing 
compound performance and generates more reliable data than traditional in vitro approaches on the 
behavior of novel agents in the oral cavity environment. 
 Preliminarily, in vitro antifungal activity against C. albicans and cytotoxicity on human keratinocyte 
cells (HaCaT), of the novel compounds were examined separately (Table 1, 2). Both MIC and IC50-C 
values obtained for Nystatin A1 were comparable with results of other researchers [43, 44]. 
Investigations showed that although derivatisation of Nystatin A1 had no apparent increased antifungal 
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action in vitro, there was a significant reduction in the toxicity level of the new compounds. To highlight 
the latter, compared with Nystatin A1, the semisynthetic derivatives displayed several-fold reduced toxic 
effects on HaCaT cells (IC50-H 50.82 vs. >300 µg ml-1). Our findings indicated that the Nystatin A1 
substitution at the nitrogen atom of amino sugar residue with a ‘bulky’ moiety, played an essential role 
for the reduction of mammalian toxicity of this drug. Previously, similar observations were described 
for Amphotericin B by Borowski and coworkers [45, 46], who showed that introduction of a large 
substituent at the amino group generated a sterical hindrance, which decreased the ability of the 
antibiotic to form lethal channels in cholesterol containing membranes, however still enabled to maintain 
a good affinity for ergosterol rich ones. Our initial results prompted us to undertake this current research 
further. 
 Interaction of Candida with the oral epithelium includes attachment and colonisation, invasion and 
tissue damage which are all important stages during the progress of infection [10, 11, 47]. In this context, 
we used a tissue model of Candida infection to examine how the novel compounds influenced these 
processes and whether they were able to inhibit the development of oral candidosis. Due to the poor 
absorption of polyenes into the tissues [12, 13, 17] and based on cytotoxicity results derived to HaCaT 
cell line, in our experiments we decided to investigate compounds at relatively high concentrations (150 
µg ml-1). 
For determination of the viability of Candida and epithelial tissue cells after the RHOE infection, we 
successfully used a live/dead assay, allowing clear distinct differentiation of the viable and dead cell 
populations of both types (Fig. 2). The studies revealed that Nystatin A1 derivatives were highly effective 
in the in vitro model of oral candidosis. Importantly, novel compounds induced a high extent of Candida 
cell death compared to the control Candida infection, with most of RHOE cells in the former appearing 
to be alive. Furthermore, the antifungal action of these derivatives was at least two-fold higher than the 
native drug and the hierarchy of activity was as follows: Nys7 ˃ Nys5 ˃ Nys1 (Fig. 3A). Subsequently, 
we demonstrated that these novel derivatives also exhibited low toxicity to human oral epithelium under 
infection conditions (Fig. 3B). In these experiments it was calculated that up to 4-fold more tissue 
keratinocytes were ‘live’ in the presence of compounds: Nys1 and Nys5 compared with Nystatin A1. In 
the case of derivative Nys7, we calculated a 2-fold reduction in toxicity. These data were in agreement 
with the cytotoxicity results on HaCaT cells, as we similarly found Nystatin A1 to be the most toxic 
antifungal. For the novel derivatives at the concentration of 150 µg ml-1, we found at least a three-fold 
decrease in toxicity to HaCaT cell line relative to native Nystatin A1 (Fig. 8). There was no statistical 
difference between the toxicity of these derivatives (P > 0.05), confirming our earlier assumptions that 
the type of substituent at the amino group of Nystatin A1 had little impact for toxicity reduction of new 
derivatives, and it was rather the substitution itself that mattered.  
Interestingly, the antifungal efficacy results obtained from the infection model contrasted somewhat 
with the previously determined MICs from broth microdilution studies, with Nystatin A1 demonstrating 
lower activity against Candida than the derivatives in the RHOE model. This effect may be associated 
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with the high tendency of the polyene antibiotics to aggregate, which is crucial in their mode of action 
[21, 48]. As described for Amphotericin B, in aqueous solutions, polyenes exist as a mixture of 
monomers, water-soluble dimers/oligomers and/or water-insoluble larger aggregates and their relative 
proportions strongly depend on concentration. Bolard et al. [48] found, that a monomeric form of 
Amphotericin B, whilst active against fungal membranes, had no toxicity towards mammalian cells. 
Meanwhile, and in contrast to water-insoluble aggregates, which were not active against both types of 
cells, water-soluble oligomers characterised for both antifungal activity and host cell toxic effects. These 
reports may assist in the understanding of our results. It is believed that Nystatin A1 has greater 
likelihood of undergoing different forms of aggregation (oligomers and larger coaggregates) than the 
new derivatives. This is because the predisposition to self-association may be hampered in the latter by 
the presence of a heavy substituent at the amino group of the molecule, and this was also previously 
observed for Amphotericin B derivatives [45]. Therefore, we hypothesise that at high concentrations, 
the water-insoluble aggregates form in the case of Nystatin A1, but probably not for the derivatives, and 
this could decrease the total antifungal action of the former. Meanwhile, under the MICs test conditions, 
lower Nystatin A1 concentrations were studied and therefore in these situations a greater extent of 
monomers and water-soluble oligomers could be formed resulting in lower MIC values (better 
antifungal activity in vitro).  
Overall, it seems that the bioavailability of the novel derivatives with reduced propensity to aggregation 
(water-solubility), has been improved relative to Nystatin A1, leading to enhanced antifungal action in 
infected tissues. However, it is difficult to ascertain this with certainty given the large size of the Nystatin 
A1 molecule, the complexity of the research model (Candida-RHOE) and limited information on 
Nystatin A1 aggregation process. 
 Additional interesting observations were made in the studies of tissue colonisation and invasion by 
Candida. Firstly, analysis showed that C. albicans ATCC 10231 extensively colonised the surface of 
the human oral epithelium and was able to invade the tissue to a high level (Fig. 5A). Similar to other 
authors [49, 50], we showed the presence of Candida biofilm on the RHOE surface and based on other 
studies involving clinical isolates of C. albicans [51, 52], we classified this strain as a ‘high invader’, 
with an uniform pattern of invasion (Fig. 9). Our measurements of the biofilm thickness were likewise 
consistent with the earlier findings [53], in which the thickness of Candida biofilm under in vitro 
conditions was determined at between 25 µm and 450 µm. Whilst yeast cells were clearly detected 
within the tissue, hyphae were the predominant fungal elements penetrating all the RHOE layers, and 
this feature has also previously been noted [51, 52, 54]. Although, yeast forms were characterised to be 
actively non-invading cells, Jacobsen et al. [55] postulated that hyphae could facilitate the entry of yeast 
into tissue and under in vivo conditions these may contribute Candida dissemination into the 
bloodstream.   
As a consequence of Candida RHOE infection, detachment of the epithelium from the basement 
membrane was evident, as were the occurrences of vacuolated spaces within the tissue structure, 
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indicating damage. The same symptoms of epithelial disruption were found in the case of C. albicans 
SC5314 (ATCC MYA-2876) [25, 54] as well as in clinical isolates [51, 56]. Finally, CLSM analysis 
supported by the levels of LDH activity, providing a quantitative indicator of tissue cells damage. The 
results showed that the Candida were responsible for epithelium destruction after 24 h, as we recorded 
the highest LDH activity only in the presence of the fungus (Fig. 7). 
Importantly, treatment of infected tissues with new polyene compounds successfully inhibited the 
Candida infection (Fig. 5C, D, E). Noteworthy, was the finding that the Nystatin A1 derivatives were 
more effective in combating Candida tissue colonisation than the native Nystatin A1, and this was 
confirmed by live/dead cell calculations. In addition, the presence of novel compounds resulted in 
thinner, less clustered and even somehow disrupted (in the case of Nys1) biofilm-like structures on tissue 
surfaces, compared to the native antibiotic. More specifically, we established that the Candida biofilm 
thickness under the effect of Nys5 and Nys7 derivatives was reduced by 29% and 36% in relation to the 
Nystatin A1. Whereas, the compound Nys1 caused a 50% decrease in fungal biofilm formation, 
comparing with the parent drug (Fig. 6).  
With respect to this, several authors [49, 50, 57] reported the resistance of in vitro Candida biofilms to 
antifungals, including Nystatin agent [58]. We also consider that the biofilm form of growth is less 
susceptible (than planktonic) to antifungal treatment, because we used high concentrations of 
compounds (150 µg ml-1), and still observed a relatively thick Candida layer (50% that of untreated 
controls) after Nystatin treatment. However, the extent of drug diffusion may also be relevant to these 
findings[59]. Notwithstanding, novel derivatives exhibited a higher anti-biofilm effect. As we 
mentioned before, this result is most likely associated with improved water solubility of the later, in 
contrast to insoluble Nystatin A1. Moreover, Chandra et al. [53] suggested that resistance of Candida 
biofilms to antifungals increases during biofilm maturation. We think it would be interesting to 
investigate the efficiency of novel compounds on different developmental Candida biofilm phases in 
the RHOE model, since in the present study we have analysed the effect of Nystatin A1 and its 
derivatives on the early stages of Candida biofilm formation.  
Furthermore, we found that C. albicans was unable to penetrate the oral epithelium after treatment with 
Nys5 and Nystatin A1, whilst at the same time, moderate and low invasion levels were still seen for 
tissues after treatment with Nys1 and Nys7. It was particularly interesting to note that the nature of 
Nystatin modification appeared to influence the extent of C. albicans invasiveness, since complete 
prevention was found only in the case of Nys5 (N-succinimidyl derivative). We also detected a positive 
relationship between the MIC (IC50-C) for the derivatives and extent of Candida invasion.  
Candida colonisation of the epithelium appeared less dependent on derivatisation, although it seemed 
that Nys1 (N-alkyl derivative) impacted differently on biofilm formation than the others, but this may 
have been associated with higher invasion level, since more fungal cells would have penetrated from 
the surface into the tissue. Nevertheless, the separation of epithelium from the base membrane was not 
found, as reported in the absence of polyene compounds. However, in terms of LDH activity, we 
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demonstrated that Nystatin A1 was 4-fold more toxic to RHOE than novel derivatives, with the latter 
resulting in statistically similar enzyme activity levels to those in the absence of Candida (Fig. 7).  
In conclusion, the present study has examined the action of novel Nystatin A1 derivatives (modified at 
the amino group) in an in vitro tissue model infected with C. albicans ATCC 10231. According to our 
knowledge, no efficiency/toxicity studies of polyene antibiotics in the Candida-RHOE model have 
previously been reported. The experiments showed that novel Nystatin derivatives were more effective 
in terms of antifungal activity, than the parent molecule. It is necessary to mention that these derivatives 
significantly inhibited Candida colonisation, including biofilm-like structure formation and highly 
reduced or completely prevented Candida invasion. We also showed, that these new polyenes were less 
toxic against keratinocyte cells, as well as the human oral epithelium compared with the natural Nystatin 
A1. Although, broth microdilution derived MICs were not extrapolated to the tissue model, we have 
proposed a possible explanation for this. We have successfully applied a live/dead stain to calculate the 
ratio of live and dead Candida and tissue cells in situ and these results were comparable with histological 
observations of RHOE colonization and invasion by C. albicans and LDH activity measurements. Based 
on live/dead calculations we demonstrated that the hierarchy of antifungal activity under tissue 
conditions were: Nys7 ˃ Nys5 ˃ Nys1 ˃ Nys, whilst the effect on the level of epithelium colonization 
and invasion by Candida seemed to be following: Nys7 ≥ Nys5 ˃ Nys1 ˃ Nys. Meanwhile, toxicity of 
the polyene antifungals assessed during viability studies decreased as follows: Nys ˃ Nys7 ˃ Nys5 ≥ 
Nys1 and similarly in terms of LDH activity level: Nys ˃ Nys7 ≥ Nys5 ≥ Nys1.  
We therefore report on the benefits of these novel Nystatin A1 derivatives as alternatives to Nystatin A1 
as the former have greatly reduced toxicity to human epithelial cells with an associated high antifungal 
activity. Further research into the mechanism of this selective toxicity exhibited by the new Nystatin A1 
derivatives is required and such studies are currently in progress.  
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Figure legends 
Figure 1. The chemical structure of Nystatin A1 and tested derivatives.  
Nys: R1=R2=H; Nys1: R1=methyl, R2=methyl; Nys2: R1=H, R2=2-(N-methylamino)-2-methylpropionyl; 
Nys3: R1=H, R2=fructosyl; Nys4: R1=H, R2=N’-3-(N’’,N’’-dimethylamino)propylsuccinimidyl; Nys5: 
R1=H, R2=N’-2-(piperidin-1-yl)ethylsuccinimidyl; Nys6: R1=3-[2-(N,N-
diethylamino)ethyl]thioureidyl; Nys7: R1=H, R2=3-[3-(N,N-dimethylamino)propyl]thioureidyl; Nys8: 
R1=H, R2=3-[2-(N,N-dimethylamino)ethyl]thioureidyl. 
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Figure 2. The viability of Candida and epithelial cells as detected by confocal scanning laser 
microscopy. Tissue devoid of fungal cells (A) and after the infection (B-F) were imaged using a 
live/dead assay. RHOE tissues were inoculated for 6 h with Candida albicans ATCC 10231 strain and 
treated with the solvent alone (B-1% v/v DMSO) or 150 µg ml-1 of antifungals for 16 h (C-Nys, D-
Nys1, E-Nys5, F-Nys7). Green cells were stained with Syto 9, while orange/red with both Syto 9 and 
propidium iodide.  
Figure 3. The ratio of green and red fluorescence of Candida albicans (A) and epithelial cells (B) after 
RHOE infection and treatment with antifungal compounds or solvent alone (1% v/v DMSO), based on 
CLSM images. Areas of green and red fluorescence for each cell type in a single image were summed, 
taken as a total and the percent of fluorescence was calculated separately for Candida and epithelial 
cells. Results for uninfected tissue control were also included (B). Fluorescence measurements were 
made using ImageJ 1.46r software. Diagrams illustrate the mean from three independent images. 
Figure 4. Confocal scanning laser microscopy of uninfected control of reconstituted human oral 
epithelium (A) and after infecting with Candida albicans ATCC 10231 strain (B). Tissues were fixed, 
sectioned and subjected to immunostaining. Keratinocytes were detected with a mouse monoclonal IgG 
pan-cytokeratin primary antibody and visualized with an Alexa Fluor 488 goat anti-mouse IgG (green). 
A Hoechst 33258 dye was used to localize epithelial cells nuclei (blue). Candida cells were 
differentiated by concanavalin A lectin conjugated with Alexa Fluor 594 (red). An arrow indicates 
keratinocytes detachment from the membrane base. 
Figure 5. Colonization and invasion of oral epithelium by Candida albicans illustrated by CLSM, in the 
absence (A) or presence (B-E) of antifungals. (A) Extensive colonization and invasion with 1% (v/v) 
DMSO; (B) moderate colonization and no invasion with Nys; (C) low colonization and moderate 
invasion with Nys1; (D) low colonization and no invasion with Nys5; (E) low colonization and low 
invasion with Nys7. Legend: +++, extensive; ++, moderate; +, low. RHOE tissues were prepared 
according to standard histological techniques and proceed with immunostaining (read legend of Figure 
4). Keratinocytes were stained in green, nuclei content were blue, while Candida cells were shown as 
red. Arrows indicate Candida albicans hyphae (yellow) and yeast cells (white) penetrating tissues.   
Figure 6. Thickness of the biofilm formed by Candida albicans on the oral epithelium surface after 
treatment with solvent (1% v/v DMSO) or polyene antifungals. Calculations were made based on CLSM 
images of immunostained RHOE sections with the use of ImageJ 1.46r software. Diagram represents 
the mean of three independent images. * Thickness of Candida layer was not statistically different in 
case of derivatives Nys5 and Nys7 (P > 0.05), according to one-way analysis of variance (ANOVA), 
followed by Tukey multiple comparisons test. 
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Figure 7. Lactate dehydrogenase (LDH) activity measured in the culture medium collected after RHOE 
infection with Candida albicans and exposure to antifungal compounds or solvent alone (1% v/v 
DMSO). LDH activity from uninfected RHOE tissues after treatment with tested agents or 1% DMSO, 
as well as from uninfected tissue controls were presented. T- means RHOE tissue. * LDH activity 
influenced by Nys was not statistically different for infected and uninfected oral epithelium (P > 0.05). 
** LDH activity in case of new derivatives was not statistically different for infected and uninfected 
oral epithelium and for uninfected oral epithelium with 1% DMSO (P > 0.05). One-way analysis of 
variance (ANOVA), followed by Tukey multiple comparisons test was used.  
Figure 8. In vitro viability of human keratinocyte cell line (HaCaT) in the presence of 150 µg ml-1 of 
antifungal compounds dissolved in DMSO and the control of solvent alone (1% v/v DMSO), measured 
after 3 days of incubation by using the CCK-8 assay. The percentage of viable cells was calculated based 
on optical density values (OD450) in relation to the drug free control. * HaCaT viability was not 
statistically different (P > 0.05) in the presence of tested derivatives. One way analysis of variance 
(ANOVA), supported by Tukey multiple comparisons test was applied. 
Figure 9. Uniform pattern of oral epithelium invasion by Candida albicans cells, labelled with 
concanavalin A lectin conjugated with Alexa Fluor 594 (red), at low (A) and high (B) magnification, 
imaged by CLSM. Dashed lines symbolize the RHOE tissue.  
Tables 
Table 1 Antifungal activity of Nystatin A1 and N-substituted derivatives  
against Candida albicans ATCC 10231 as determined by broth microdilution 
Compound MIC (µg ml-1) IC50-C (µg ml-1) 
Nys * 0.5 0.21 
N-alkyl derivatives 
Nys1 4 2.81 
N-aminoacyl derivatives 
Nys2 4 2.61 
N-fructosyl derivatives 
Nys3 8 3.06 
N-succinimidyl derivatives 
Nys4 8 3.89 
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Nys5 2 1.19 
Thioureidyl derivatives 
Nys6 8 4.65 
Nys7 4 2.81 
Nys8 4 2.35 
* Breakpoint for resistance to Nystatin A1: MIC ≥ 16 (µg ml-1) [60] 
 
Table 2 Cytotoxicity of Nystatin A1 and N-substituted derivatives  
to HaCaT cell line defined by using the Cell Counting Kit-8 
Compound IC50-H (µg ml-1) 
Nys 50.82 
N-alkyl derivatives 
Nys1 >300 
N-aminoacyl derivatives 
Nys2 >300 
N-fructosyl derivatives 
Nys3 >300 
N-succinimidyl derivatives 
Nys4 >300 
Nys5 >300 
Thioureidyl derivatives 
Nys6 >300 
Nys7 >300 
Nys8 >300 
 
Table 3 Candida albicans colonisation and invasion of reconstituted human oral epithelium  
influenced by Nystatin A1 and N-substituted derivatives and evaluated by confocal laser scanning 
microscopy 
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Sample Colonisation Invasion 
1% DMSO +++ +++ 
Nys ++ none 
Nys1 + ++ 
Nys5 + none 
Nys7 + + 
Legend: +++, extensive; ++, moderate; +, low. 
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